vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and PROCORE TECHNOLOGIES, INC. (PCOR). Click either name above to swap in a different company.
PROCORE TECHNOLOGIES, INC. is the larger business by last-quarter revenue ($349.1M vs $196.0M, roughly 1.8× Axsome Therapeutics, Inc.). PROCORE TECHNOLOGIES, INC. runs the higher net margin — -10.8% vs -14.6%, a 3.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 15.6%). PROCORE TECHNOLOGIES, INC. produced more free cash flow last quarter ($109.2M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 13.8%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Procore Technologies is an American construction management software as a service company founded in 2002, with headquarters in Carpinteria, California. Procore hosts a platform to connect those involved in the construction industry on a global platform. The software allows for the creation of simplified workflows and displays a consolidated view of construction products that includes the tracking of tasks, management of project workflows, and scheduling.
AXSM vs PCOR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $349.1M |
| Net Profit | $-28.6M | $-37.6M |
| Gross Margin | — | 80.1% |
| Operating Margin | -13.8% | -12.3% |
| Net Margin | -14.6% | -10.8% |
| Revenue YoY | 65.0% | 15.6% |
| Net Profit YoY | 61.9% | 39.6% |
| EPS (diluted) | $-0.55 | $-0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $349.1M | ||
| Q3 25 | $171.0M | $338.9M | ||
| Q2 25 | $150.0M | $323.9M | ||
| Q1 25 | $121.5M | $310.6M | ||
| Q4 24 | $118.8M | $302.0M | ||
| Q3 24 | $104.8M | $295.9M | ||
| Q2 24 | $87.2M | $284.3M | ||
| Q1 24 | $75.0M | $269.4M |
| Q4 25 | $-28.6M | $-37.6M | ||
| Q3 25 | $-47.2M | $-9.1M | ||
| Q2 25 | $-48.0M | $-21.1M | ||
| Q1 25 | $-59.4M | $-33.0M | ||
| Q4 24 | $-74.9M | $-62.3M | ||
| Q3 24 | $-64.6M | $-26.4M | ||
| Q2 24 | $-79.3M | $-6.3M | ||
| Q1 24 | $-68.4M | $-11.0M |
| Q4 25 | — | 80.1% | ||
| Q3 25 | — | 79.7% | ||
| Q2 25 | — | 79.1% | ||
| Q1 25 | — | 79.1% | ||
| Q4 24 | — | 81.2% | ||
| Q3 24 | — | 81.4% | ||
| Q2 24 | — | 83.1% | ||
| Q1 24 | — | 83.0% |
| Q4 25 | -13.8% | -12.3% | ||
| Q3 25 | -27.0% | -4.4% | ||
| Q2 25 | -24.5% | -9.3% | ||
| Q1 25 | -46.9% | -11.7% | ||
| Q4 24 | -61.1% | -21.9% | ||
| Q3 24 | -59.8% | -12.3% | ||
| Q2 24 | -89.5% | -5.2% | ||
| Q1 24 | -89.7% | -7.0% |
| Q4 25 | -14.6% | -10.8% | ||
| Q3 25 | -27.6% | -2.7% | ||
| Q2 25 | -32.0% | -6.5% | ||
| Q1 25 | -48.9% | -10.6% | ||
| Q4 24 | -63.1% | -20.6% | ||
| Q3 24 | -61.7% | -8.9% | ||
| Q2 24 | -91.0% | -2.2% | ||
| Q1 24 | -91.1% | -4.1% |
| Q4 25 | $-0.55 | $-0.25 | ||
| Q3 25 | $-0.94 | $-0.06 | ||
| Q2 25 | $-0.97 | $-0.14 | ||
| Q1 25 | $-1.22 | $-0.22 | ||
| Q4 24 | $-1.54 | $-0.42 | ||
| Q3 24 | $-1.34 | $-0.18 | ||
| Q2 24 | $-1.67 | $-0.04 | ||
| Q1 24 | $-1.44 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $768.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.3B |
| Total Assets | $689.8M | $2.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $768.5M | ||
| Q3 25 | $325.3M | $684.0M | ||
| Q2 25 | $303.0M | $620.9M | ||
| Q1 25 | $300.9M | $566.7M | ||
| Q4 24 | $315.4M | $775.4M | ||
| Q3 24 | $327.3M | $756.9M | ||
| Q2 24 | $315.7M | $735.4M | ||
| Q1 24 | $331.4M | $744.6M |
| Q4 25 | $88.3M | $1.3B | ||
| Q3 25 | $73.7M | $1.2B | ||
| Q2 25 | $73.1M | $1.2B | ||
| Q1 25 | $53.2M | $1.2B | ||
| Q4 24 | $57.0M | $1.3B | ||
| Q3 24 | $92.9M | $1.3B | ||
| Q2 24 | $102.9M | $1.3B | ||
| Q1 24 | $144.0M | $1.2B |
| Q4 25 | $689.8M | $2.2B | ||
| Q3 25 | $669.3M | $2.1B | ||
| Q2 25 | $639.8M | $2.0B | ||
| Q1 25 | $596.7M | $1.9B | ||
| Q4 24 | $568.5M | $2.1B | ||
| Q3 24 | $561.5M | $2.0B | ||
| Q2 24 | $548.2M | $2.0B | ||
| Q1 24 | $545.7M | $1.9B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $114.9M |
| Free Cash FlowOCF − Capex | $-18.7M | $109.2M |
| FCF MarginFCF / Revenue | -9.6% | 31.3% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $282.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $114.9M | ||
| Q3 25 | $1.0M | $88.5M | ||
| Q2 25 | $-32.4M | $30.8M | ||
| Q1 25 | $-43.4M | $66.0M | ||
| Q4 24 | $-26.2M | $29.1M | ||
| Q3 24 | $-18.6M | $39.3M | ||
| Q2 24 | $-30.1M | $58.7M | ||
| Q1 24 | $-53.5M | $69.1M |
| Q4 25 | $-18.7M | $109.2M | ||
| Q3 25 | $988.0K | $83.1M | ||
| Q2 25 | $-32.4M | $27.9M | ||
| Q1 25 | $-43.7M | $62.0M | ||
| Q4 24 | $-26.2M | $17.4M | ||
| Q3 24 | $-18.7M | $35.7M | ||
| Q2 24 | $-30.2M | $56.8M | ||
| Q1 24 | $-53.6M | $67.1M |
| Q4 25 | -9.6% | 31.3% | ||
| Q3 25 | 0.6% | 24.5% | ||
| Q2 25 | -21.6% | 8.6% | ||
| Q1 25 | -36.0% | 20.0% | ||
| Q4 24 | -22.1% | 5.8% | ||
| Q3 24 | -17.9% | 12.1% | ||
| Q2 24 | -34.6% | 20.0% | ||
| Q1 24 | -71.4% | 24.9% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 1.6% | ||
| Q2 25 | 0.0% | 0.9% | ||
| Q1 25 | 0.3% | 1.3% | ||
| Q4 24 | 0.0% | 3.9% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.1% | 0.7% | ||
| Q1 24 | 0.1% | 0.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
Segment breakdown not available.
PCOR
| US | $298.3M | 85% |
| Non Us | $50.9M | 15% |
